Cardiovascular Safety Profile of Pioglitazone Along With Vitamin E

Abstract

The increase incidence of obesity, stress and aging in genetically predisposed population has lead to an increase in the incidence of type 2 diabetes mellitus. This led to the development of new drugs such as thiazolidinediones (TZDs) which is a agonist of Peroxisome Proliferator-Activated Receptor (PPARgamma).Pioglitazone is a TZD have recently been identified for its severe cardiovasculara complication. Pioglitazone is oral hypoglycemic agent which has been shown to be effective by lowering insulin resistance.Due to its cardiovasculaqr risk factor it is combined with adjunct vitamin E,an antioxidant in the present study. The safety and efficacy of pioglitazone are increased several fold along with vitamin E.